计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A648809-1mg |
1mg |
期货 ![]() |
| |
| A648809-5mg |
5mg |
期货 ![]() |
| |
| A648809-10mg |
10mg |
期货 ![]() |
| |
| A648809-25mg |
25mg |
期货 ![]() |
|
| 别名 | 盐酸阿普拉韦罗 |
|---|---|
| 英文别名 | ONO-4128 | Tox21_300211 | UNII-8YYQ7W3Z76 | Aplaviroc HCl | 1,2-Dithiole-3-thione, 4-phenyl- | HY-17450A | Maybridge1_000088 | Benzoic acid, 4-(4-(((3R)-1-butyl-3-((R)-cyclohexylhydroxymethyl)-2,5-dioxo-1,4,9- triazaspiro(5.5)undec-9-yl)methyl)phenoxy)-, |
| 规格或纯度 | ≥99% |
| 英文名称 | Aplaviroc hydrochloride |
| 生化机理 | 盐酸阿普拉韦罗(AK 602)是一种 SDP 衍生物,是一种 CCR5 拮抗剂,对 HIV-1 Ba-L 、HIV-1 JRFL 和 HIV-1 MOKW 的 IC 50 s 为 0.1-0.4 nM。 |
| 储存温度 | 2-8°C储存,干燥 |
| 运输条件 | 冰袋运输 |
| 作用类型 | 拮抗剂 |
| 作用机制 | C-C 趋化因子受体 5 型拮抗剂 |
| 产品介绍 |
Aplaviroc (AK 602) hydrochloride, a SDP derivative, is a CCR5 antagonist, with IC 50 s of 0.1-0.4 nM for HIV-1 Ba-L , HIV-1 JRFL and HIV-1 MOKW . In Vitro Aplaviroc exerts potent activity against three wild-type R5 HIV-1 strains (HIV-1 Ba-L , HIV-1 JRFL and HIV-1 MOKW ) with IC 50 values of 0.1 to 0.4 nM. Aplaviroc is substantially more potent than two previously published CCR5 inhibitors, E921/TAK-779 and AK671/SCH-C. Aplaviroc suppresses the infectivity and replication of two HIV-1 MDR variants, HIV-1 MM and HIV-1 JSL , at extremely low concentrations (IC 50 values of 0.4 to 0.6 nM). Aplaviroc binds to CCR5 with high affinity. The K d values thus determined for Aplaviroc, E913, E921/TAK-779, and AK671/SCH-C are 2.9±1.0, 111.7±3.5, 32.2±9.6, and 16.0±1.5 nM, respectively. Aplaviroc potently blocks rgp120/sCD4 binding to CCR5 with an IC 50 value of 2.7 nM. These results suggest that the potent activity of Aplaviroc against R5 HIV-1 stems from its binding to ECL2B and/or its vicinity with high affinity, resulting in inhibition of gp120/CD4 binding to CCR5. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo The concentration of Aplaviroc (AK602) reached the maximal concentration immediately after intraperitoneal administration and decreased rapidly. Aplaviroc (AK602, 60 mg/kg, bid, daily) suppresses R5 HIV-1 viremia in hu-PBMC-NOG mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: hu-PBMC-NOG mice. Dosage: 60 mg/kg. Administration: Single intraperitoneal administration, bid, daily. Result: The numbers of CD4 + cells/μL in saline-treated mice were significantly less than those of AK602-treated, ddI-treated, or uninfected mice. Form:Solid IC50& Target:HIV-1 Ba-L 0.4 nM (IC 50 ) HIV-1 JRFL 0.1 nM (IC 50 ) HIV-1 MOKW 0.2 nM (IC 50 ) CCR5 |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid;hydrochloride |
| INCHI | 1S/C33H43N3O6.ClH/c1-2-3-19-36-30(38)28(29(37)24-7-5-4-6-8-24)34-32(41)33(36)17-20-35(21-18-33)22-23-9-13-26(14-10-23)42-27-15-11-25(12-16-27)31(39)40;/h9-16,24,28-29,37H,2-8,17-22H2,1H3,(H,34,41)(H,39,40);1H/t28-,29-;/m1./s1 |
| InChi Key | QNNBMSGFNQRUEH-PQQSRXGVSA-N |
| Smiles | CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)C(C5CCCCC5)O.Cl |
| Isomeric SMILES | CCCCN1C(=O)[C@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)[C@@H](C5CCCCC5)O.Cl |
| 关联CAS | 461023-63-2 |
| PubChem CID | 6918686 |
| 分子量 | 614.17 |
| 溶解性 | DMSO : 200 mg/mL (325.64 mM; Need ultrasonic) H2O : <0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble) |
|---|---|
| 分子量 | 614.200 g/mol |
| XLogP3 | |
| 氢键供体数Hydrogen Bond Donor Count | 4 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 10 |
| 精确质量Exact Mass | 613.292 Da |
| 单同位素质量Monoisotopic Mass | 613.292 Da |
| 拓扑极表面积Topological Polar Surface Area | 119.000 Ų |
| 重原子数Heavy Atom Count | 43 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 915.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 2 |